(Q44676392)

5 December 2017

title

DPP4 inhibitor-induced polyarthritis: a report of three cases (English)

1 reference

5 December 2017

Etienne Crickx

1

1 reference

5 December 2017

Ibrahim Marroun

2

1 reference

5 December 2017

Christine Veyrie

3

1 reference

5 December 2017

Christine Le Beller

4

1 reference

5 December 2017

Yoland Schoindre

5

1 reference

5 December 2017

Florence Bouilloud

6

1 reference

5 December 2017

Olivier Blétry

7

1 reference

5 December 2017

Jean-Emmanuel Kahn

8

1 reference

5 December 2017

publication date

5 March 2013

1 reference

Rheumatology International

5 December 2017

published in

1 reference

5 December 2017

volume

34

1 reference

5 December 2017

issue

2

1 reference

5 December 2017

page(s)

291-292

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

RS3PE in association with dipeptidyl peptidase-4 inhibitor: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2710-7

10.1007/S00296-013-2710-7

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference